The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Outcomes of Two Trials of Oxygen-Saturation Targets in Preterm Infants.
The safest ranges of oxygen saturation in preterm infants have been the subject of debate. ⋯ Use of an oxygen-saturation target range of 85 to 89% versus 91 to 95% resulted in nonsignificantly higher rates of death or disability at 2 years in each trial but in significantly increased risks of this combined outcome and of death alone in post hoc combined analyses. (Funded by the Australian National Health and Medical Research Council and others; BOOST-II Current Controlled Trials number, ISRCTN00842661, and Australian New Zealand Clinical Trials Registry number, ACTRN12605000055606.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ovarian cancer. We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients receiving and those not receiving bevacizumab. ⋯ Overall, weekly paclitaxel, as compared with paclitaxel administered every 3 weeks, did not prolong progression-free survival among patients with ovarian cancer. (Funded by the National Cancer Institute and Genentech; GOG-0262 ClinicalTrials.gov number, NCT01167712.).
-
Comment Letter
Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.